Monoclonal Antibodies May Prevent Malaria

In COVID-19, Latest News by Precision Vaccinations

One dose of a new monoclonal antibody discovered and developed at the US National Institutes of Health (NIH) safely prevented malaria for up to nine months in people exposed to the malaria parasite.
This small clinical trial is the first to demonstrate that a monoclonal antibody can prevent malaria in people.
The trial was sponsored and conducted by scientists from the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, and was funded by NIAID.

Read More